According to the company, the transaction is expected to close in a span of five or six months.
Transgene Biotek managing director KK Rao said the deal would help the company lay emphasis on monetising the sale of underutilised bio-generic drug assets.
The company is currently manufacturing DHA, an Omega-3 Fatty acid used in the nutraceuticals and health supplements market.
Transgene is also developing APIs (active pharma ingredients) and is likely to begin the production of a second API, Tacrolimus.